New drug attack on Hard-to-Treat breast cancer before surgery
NCT ID NCT05919108
Summary
This study is testing if adding a drug called neratinib to standard hormone therapy before surgery helps treat a specific type of breast cancer. It is for people with stage I-III lobular breast cancer that has a specific genetic change (HER2 mutation). The goal is to see if this combination shrinks the tumor better before surgery, potentially leading to better long-term control of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor College of Medicine
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact
-
Emory University/ Winship Cancer Institute
NOT_YET_RECRUITINGAtlanta, Georgia, 30322, United States
Contact
-
University of Pittsburgh Medical Center
NOT_YET_RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact
-
University of Texas, Southwestern
RECRUITINGDallas, Texas, 75390, United States
Contact
Contact Email: •••••@•••••
Contact
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.